Prior authorization required for many antiemetics

Prior authorization (PA) is required for many antiemetic products; approvals are tied to diagnosis‑specific criteria (e.g., prevention of CINV for High or Moderate emetic risk parenteral chemotherapy) and may include quantity limits. Approval lengths up to 12 months may be granted for prevention of chemotherapy‑induced nausea and vomiting for Medicare and Medicaid members.

• PA applies to NK1 RA and 5HT3 RA products when diagnostic criteria are met
• Approval length: as requested, up to 12 months
• Override types: PA and QL

PA may be required for J‑/Q‑coded products

Prior authorization may be required per the member’s benefit document for injectable and specialty antiemetic products billed with the listed HCPCS J‑ and Q‑codes; providers must confirm PA requirements with the member‑specific benefit plan.

• Examples of injectable/specialty codes: J0185, J1434, J1453, J1454, J1456, J1626, J1627, J2405, J2468, J2469, J8501, J8655, J8670, Q0162, Q0166
• Confirm PA via member benefit document prior to administration/billing

HCPCS / J / Q codes listed (reference only)

The policy lists specific HCPCS, J‑, and Q‑codes for injectable and oral antiemetics to be used for billing and prior authorization reference; the chunks here enumerate those codes but do not specify PA applicability.

• Included procedure codes: J1456, J1626, J1627, J2405, J2468, J2469, J8501, J8655, J8670, Q0162, Q0166
• Diagnosis codes listed for claims: R11.0, R11.10, R11.2, T45.1X5A/D/S, Z51.11

Trial of preferred NK1 RA/5HT3 RA required before non‑preferred agents

A trial of adequate dose and duration of a preferred NK1 RA or preferred 5HT3 RA is required before a non‑preferred NK1 RA, 5HT3 RA, or NK1/5HT3 combination product will be approved, unless alternative attestation criteria are met.

• Required: history of trial to a preferred product with minimal clinical response documented
• Alternative: physician attestation of expected superiority or documentation of intolerance/contraindication to preferred agent

No explicit step sequence — follow NCCN/ASCO guidance

The policy does not provide a rigid sequencing algorithm; instead it references guideline‑based regimen selection (NCCN/ASCO) and notes that oral agents are included only when administered prior to infusion.

• Follow NCCN/ASCO regimen recommendations based on emetogenic risk and route
• Oral antiemetics are only included when given prior to chemotherapy infusion (not when self‑administered outside infusion)

No additional step therapy requirements specified

These policy chunks do not specify additional step therapy requirements beyond the trial/attestation language already provided.

Physician attestation and prior trial documentation required for non‑preferred agents

When requesting a non‑preferred NK1 RA, 5HT3 RA, or combination product, the physician must attest to either prior trial and inadequate response to a preferred agent or document intolerance/contraindication and state that the same issue is not expected with the requested non‑preferred product.

• Physician attestation must state clinical rationale (superiority, intolerance, or contraindication)
• Document prior trial of adequate dose/duration if applicable

Submit clinical documentation supporting indication and risk factors

Documentation submitted for diagnosis‑specific approvals must support the emetogenicity of the chemotherapy (High or Moderate risk), indicate combination use when required (e.g., NK1 plus 5HT3 RA), and include patient risk factors when applicable (younger age, female sex, low alcohol use, prior CINV, motion/morning sickness, high anxiety).

• Show chemotherapy emetogenicity (High or Moderate) used to justify antiemetic selection
• Document combination use (NK1 RA with 5HT3 RA) when required by criteria
• Include relevant patient risk factors for CINV

Document administration route and timing (oral agents only if given before infusion)

Document the administration route and timing relative to chemotherapy; oral antiemetics are only included when administered prior to infusion and are not covered when self‑administered outside the infusion setting.

• Specify route (IV, oral) and timing relative to chemotherapy on documentation/claim
• Oral agents are included only if given prior to the chemotherapy infusion

Include listed HCPCS/J/Q codes and an associated diagnosis code on claims

Providers should bill using the HCPCS/J‑ and Q‑codes listed in the guideline and include an associated diagnosis code such as R11.0, R11.10, R11.2, T45.1X5A/D/S, or Z51.11 to reflect nausea/vomiting or an encounter for antineoplastic chemotherapy.

• Use applicable HCPCS/J/Q procedure code for the antiemetic administered
• Include supporting diagnosis code (e.g., Z51.11 for chemotherapy encounter) on the claim

Missing step therapy or attestation risks denial or delay

Failure to meet the step therapy criteria — for example, no documented trial of a preferred product or lack of physician attestation of superiority/intolerance — may result in denial or delay of coverage for non‑preferred NK1 RA, 5HT3 RA, or combination products.

• Denial risk if prior trial or attestation documentation is missing
• May cause coverage delay while documentation is obtained or reviewed

Coverage constrained by member benefit or state mandates

Coverage may be denied if the member‑specific benefit plan document or applicable state mandates do not authorize experimental, investigational, or otherwise unproven treatments; consult the member’s benefit document.

• Benefit plan or state mandates may supersede policy language
• CGP participants may have different coverage for investigational/unproven treatments — verify member benefit

Use listed HCPCS and diagnosis codes to support claims and PAs

The policy lists HCPCS and diagnosis codes that are relevant to billing and claims support; use these listed codes to substantiate claims and prior authorization requests where applicable.

• Reference the guideline’s HCPCS/J/Q listings when preparing claims and PAs
• Inclusion of a code in the guideline is for reference and does not guarantee reimbursement — confirm with benefit plan